Celsion Corporation (CLSN)

[GD]

May be I am reading into too much, but to me these changes in Prof. Lencioni's view
is a sign OPTIMA OS results are a repeat or better than subgroup data:
April 12, 2018 CLSN PR:
Prof. Lencioni’s presentation: "The company’s ongoing second Phase III study, the OPTIMA Study, is designed to test this survival benefit hypothesis. If this hypothesis bears out in the OPTIMA Study, this would be very meaningful and highly encouraging as there are few available treatments effective in prolonging survival in HCC.”
Sept 23, 2019 CLSN PR: (Coincidence?, Sept 23 is exactly 6 weeks from Aug 128 event datalock PR, and also in the PR is DMC meeting is scheduled for late OCT,
is the OS data available by Sept 23???!!!)
Prof. Lencioni comments: "The Company’s ongoing second Phase III study, the OPTIMA Study, is designed to test this survival benefit hypothesis. If this hypothesis bears out in the OPTIMA Study, ThermoDox® will be the first and only FDA approved drug for the treatment of HCC with curative intent.”

From "very meaningful and highly encouraging" treatment to "the treatment of HCC with curative intent”, Prof. Lencioni is OPTIMA trial study co-chairman, he is the one should have very clear view how OPTIMA is going from blinded data, IMO.